$29.86
+4.8%STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Last Annual Value
183.56M
3-Year CAGR
9%
5-Year CAGR
18%
10-Year CAGR
16%
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() STAAR Surgical Company NASDAQ:STAA | 183.56M | 0.6% | 10.5% | 13.7% | |
![]() Tourmaline Bio, Inc. NASDAQ:TRML | 22.75M | 20.4% | 700.5% | N/A | |
![]() ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 33.19M | 9.0% | 8.6% | N/A | |
![]() Azenta, Inc. NASDAQ:AZTA | 251.16M | -3.7% | 5.9% | 6.8% | |
![]() Beta Bionics, Inc. NASDAQ:BBNX | 92.43M | 56.3% | N/A | N/A | |
![]() Kestra Medical Technologies, Ltd. NASDAQ:KMTS | 114.94M | 28.6% | 52.6% | N/A | |
![]() Terns Pharmaceuticals, Inc. NASDAQ:TERN | 32.23M | -6.2% | 10.5% | N/A | |
![]() NovoCure Limited NASDAQ:NVCR | 417.73M | 2.2% | 9.7% | 14.2% | |
![]() Pulse Biosciences, Inc. NASDAQ:PLSE | 32.03M | 26.6% | -1.1% | 27.0% | |
![]() BioLife Solutions, Inc. NASDAQ:BLFS | 55.37M | -0.4% | 2.9% | 22.0% | |
![]() Precigen, Inc. NASDAQ:PGEN | 70.13M | 20.2% | N/A | -6.8% |
Continue your STAA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.